Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | USP8 | P40818 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177851 | 0.90 | LMNA (0.75) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL634004 | 0.90 | MEN1 (0.75) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL5386848 | 0.90 | LMNA (0.75) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL5831181 | 0.88 | MEN1 (0.64) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL5401437 | 0.87 | LMNA (0.71) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL5832041 | 0.86 | ALDH1A1 (0.66) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL2197860 | 0.86 | MEN1 (0.70) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL5830757 | 0.85 | MEN1 (0.68) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL5831014 | 0.85 | MEN1 (0.68) | MEN1LMNAALOX12HTTKMT2A | |
| SCHEMBL11891715 | 0.85 | ALDH1A1 (0.69) | MEN1LMNAALOX12HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | CPT1A, HSD11B1, CES1 | MEN1 903/4885LMNA 1897/4885ALOX12 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.